PIP: 50 healthy women aged 27-39 were screened and participated in an clinical study on the vaginal application of levonorgestrel (LNG) as a contraceptive. Among the 50 women, 27 had live births and 23 had abortions as the result of their last pregnancy within 5 years. They had regular menstruation for the past 3 months, and no disease of the liver, heart, or urinary system. 0.75 mg LNG tablets produced by Beijing Pharmaceutical Manufacturers were chosen for the study. All the participants were instructed to put one tablet into the upper end of vagina every other day from the seventh day of the menstrual cycle with 8 tablets per cycle. 258 cycles of pills were used by the 50 participants. 953 acts of sexual intercourse were recorded during the study with 3.69 per cycle on average. Even though pills were missed in 28 cycles, there was only 1 case of pregnancy. The pill use affected the duration of the menstrual cycle, with mean duration of 27.8 days + or - 4.1 days. Vaginal bleeding occurred in 13 cycles (4.06). Side effects including sickness, backache, breast pain, and increased vaginal secretion occurred only in 3.89% of the cycles, which was much lower than in oral administration. No vaginal infection occurred in any of the cases. 10 participants dropped out before the end of study, including 1 who became pregnant. 44 participants, including 4 drop-outs, wanted to continue with the method. Vaginal application of progesterone is a promising means of contraception. But, as the study has a small sample size and short duration, is further research to prove the advantage of vaginal application over oral administration in terms of effectiveness, side effects, longterm safety, an acceptability.